Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium)

Strengthening and enhancing domestic biopharmaceutical manufacturing capabilities

Request for Project Proposals for Domestic Capability Building Activity

Currently, there is no domestic manufacturing capability for viral hemorrhagic fever vaccines. To strengthen national preparedness and response to potential viral outbreaks, the U.S. government aims to establish this critical capability. This initiative will involve the technology transfer of existing candidate vaccine production processes, including bulk drug substance and drug product activities (formulation and fill/finish), from international manufacturing sites to one or more U.S.-based Contract Development and Manufacturing Organizations (CDMOs).

Submissions Due: Dec. 11, 2025 at 1 p.m. ET

Learn More

Partnership Opportunities

Seeking partnerships to rapidly respond to future Public Health Emergencies (PHE)

Apply to Join the BioMaP-Consortium

No Cost Barrier for Entry

Pre-negotiated Terms

Fast & Flexible Partnerships

Networking & Engagement with Industry

Industrial Base Expansion of Supply Chain

Engage with the network of organizations and personnel that provide all goods and services in support of the entire biomanufacturing process, to include, but not limited to, raw materials, consumables, and fill-finish services.

Biomanufacturing Capacity Expansion and Reservation

Prepare and provide timely, integrated, and sufficient medical countermeasures in response to emerging pathogens with pandemic potential through establishing, expanding and/or reserving drug substance and/or drug product manufacturing capacities.

Advanced Biomanufacturing Technologies

Address new and emerging technologies, that enhance existing capabilities that increase the speed, quality, safety, yield, efficiency of the biomanufacturing process or the safety, quality, effectiveness, or availability of the resulting biopharmaceutical drug product.